Valuation : Agios Pharmaceuticals, Inc.

Market Cap 2.07B 1.78B 1.68B 1.53B 2.86B 198B 2.88B 19.98B 7.69B 100B 7.76B 7.59B 318B P/E 2026 *
-6.1x
P/E 2027 * -9.39x
Enterprise Value 1.81B 1.56B 1.47B 1.34B 2.5B 173B 2.52B 17.49B 6.73B 87.77B 6.8B 6.65B 279B EV / Sales 2026 *
9.92x
EV / Sales 2027 * 5.49x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day-3.52%
1 week+1.48%
Current month-0.18%
1 month+3.16%
3 months+16.41%
6 months+18.97%
Current year+23.51%
1 week 32.23
Extreme 32.23
35.38
1 month 32.22
Extreme 32.22
35.98
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 08/08/2022
Director of Finance/CFO 51 26/09/2022
Chief Tech/Sci/R&D Officer 47 01/09/2021
Director TitleAgeSince
Director/Board Member 66 09/12/2014
Director/Board Member 73 23/06/2015
Director/Board Member 73 27/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
04/08/26 Sell

Chief Technology Officer

-30,000 0.0504%
08/07/26 Free

Director

2,894 0.0049%
01/07/26 Exercice

Chief Technology Officer

20,757 0.0349%
Change 5-day change 1-year change 3-year change Capi.($)
-3.52%+1.48%-5.77%+25.12% 2.07B
-0.25%-0.96%+45.25%+102.76% 68.52B
-1.09%-6.20%+30.50%+74.05% 62.88B
-1.34%+0.52%-12.74%+380.51% 28.13B
-2.74%-3.53%+26.13%+13.50% 25.56B
-1.95%-6.47%-4.73%-18.42% 24.65B
-2.39%-5.19%+17.75%-19.64% 19.81B
-1.86%+1.15%+205.44%+353.89% 17.69B
-1.37%-3.77%-9.38%+528.34% 14.66B
-1.05%-1.98%+53.74%+163.57% 14.45B
Average -1.76%-1.05%+34.62%+160.37% 27.84B
Weighted average by Cap. -1.31%-1.39%+35.29%+137.65%

Financials

2026 *2027 *
Net sales 182M 157M 148M 135M 252M 17.45B 254M 1.76B 679M 8.85B 685M 670M 28.11B 352M 302M 285M 260M 486M 33.61B 490M 3.4B 1.31B 17.05B 1.32B 1.29B 54.14B
Net income -338M -291M -274M -250M -467M -32.32B -471M -3.27B -1.26B -16.39B -1.27B -1.24B -52.07B -229M -197M -186M -170M -317M -21.93B -320M -2.22B -853M -11.13B -862M -843M -35.34B
Net Debt -258M -222M -209M -190M -356M -24.63B -359M -2.49B -958M -12.49B -967M -946M -39.68B -137M -118M -111M -102M -190M -13.14B -192M -1.33B -511M -6.66B -516M -505M -21.16B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
10/09/26 $33.62 -2.92% 215,209
09/09/26 $34.63 +3.22% 1,024,568
08/09/26 $33.55 +1.36% 816,359
04/09/26 $33.10 -0.09% 480,161
03/09/26 $33.13 -2.93% 516,035
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
34.63USD
Average target price
45.75USD
Spread / Average Target
+32.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!